thrombopoietin receptor

Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.

4"-O-Glucosylvitexin (glucosylvitexin) inhibits TPO activity.

Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

Imidazole is a planar 5-membered ring and a highly polar compound. It has been used extensively as a corrosion inhibitor. Imidazole is incorporated into many important biological molecules.

Hetrombopag olamine is a non-peptide thrombopoietin (TPO) receptor agonist with oral activity.

(E/Z)-Eltrombopag-13C4 is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC50 of 3.3 nM. It effectively mimics TPO by stimulating platelet production through activation of the intracellular signaling system, facilitating platelet and megakaryocyte generation from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 [CYP] 2C9 and CYP3A.

Hetrombopag is a potent agonist of the thrombopoietin receptor. Hetrombopag is well tolerated and has a controlled safety profile. hetrombopag has potential for studies in immune thrombocytopenia.

Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.

Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.

Eltrombopag Methyl Ester, a derivative of Eltrombopag, functions as a thrombopoietin (Tpo) receptor agonist to enhance platelet production and is employed in the study of certain thrombocytopenia variants.

Rafutrombopag, a thrombopoietin (TPO) agonist, is a chemical compound.

PKHB1 is a thrombospondin-1 peptide mimetic known for its antitumor properties. It induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. Additionally, PKHB1 promotes immune system activation through immunogenic cell death in breast cancer cells.

Cys-PKHB1 (Cys-txCD47) is a polypeptide consisting of a cysteine (Cys) residue coupled with PKHB1, which is a CD47 agonist peptide that acts as a thrombospondin-1 peptide mimetic with anti-tumor properties. In breast cancer cells, PKHB1 induces mitochondrial changes, ROS production, intracellular Ca+ accumulation, and calcium-dependent cell death. Additionally, PKHB1 activates the immune system by inducing immunogenic cell death in breast cancer cells.

Cys-PKHB1 (Cys-txCD47) TFA is a polypeptide consisting of a cysteine (Cys) residue conjugated with PKHB1, which is a CD47 agonist peptide that mimics the anti-tumor effects of thrombospondin-1 peptides. In breast cancer cells, PKHB1 induces mitochondrial changes, ROS production, intracellular accumulation of Ca+, and calcium-dependent cell death. Furthermore, PKHB1 activates the immune system through immunogenic cell death of breast cancer cells.

Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials.

MF266-1, a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of osteoarthritis and rheumatoid.

Romiplostim is an Fc-peptide fusion antibody and thrombopoietin (TPO) agonist. It enhances platelet production by activating the TPO receptor, thereby stimulating JAK/STAT, MAPK pathways, and multiple anti-apoptotic pathways. It is indicated for the treatment of immune thrombocytopenic purpura (ITP).

Avatrombopag-D8 is a deuterated compound of Avatrombopag. Avatrombopag (T7417) has a CAS number of 570406-98-3. Avatrombopag (T7417) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.

Lusutrombopag-D13 is a deuterated compound of Lusutrombopag. Lusutrombopag (TQ0223) has a CAS number of 1110766-97-6. Lusutrombopag (TQ0223) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

(E/Z)-Eltrombopag 13C4 (Standard) is a reference standard of (E/Z)-Eltrombopag 13C4 intended for quantitative analysis, quality control, and related biochemical research applications. (E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.